Your browser doesn't support javascript.
Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use.
Ahmed, Sagheer; Khan, Saeed; Imran, Imran; Al Mughairbi, Fadwa; Sheikh, Fahad Sultan; Hussain, Javid; Khan, Ajmal; Al-Harrasi, Ahmed.
  • Ahmed S; Department of Basic Medical Sciences, Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad 44000, Pakistan.
  • Khan S; Dow International Medical College, Dow University of Health Sciences, Karachi 74200, Pakistan.
  • Imran I; Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan.
  • Al Mughairbi F; Department of Clinical Psychology, College of Medicine & Health Sciences, UAE University, Al Ain 15551, United Arab Emirates.
  • Sheikh FS; Department of Basic Medical Sciences, Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad 44000, Pakistan.
  • Hussain J; Department of Biological Sciences and Chemistry, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman.
  • Khan A; Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman.
  • Al-Harrasi A; Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, Birkat Al Mauz, Nizwa 616, Oman.
Vaccines (Basel) ; 9(8)2021 Jul 29.
Article in English | MEDLINE | ID: covidwho-1335263
ABSTRACT
As per the World Health Organization (WHO), more than 288 vaccines against COVID-19 are being developed, with an estimated 184 being presently investigated in the pre-clinical phases, while 104 of these vaccine candidates are at various stages of clinical trials. Twelve of these are in the advanced stages of clinical investigation, and promising results in the phase 3 trials have already paved the way for their regulatory approval and subsequent dissemination for global use. Preliminary and interim results of some of these candidate vaccines are being analyzed for public dissemination. Some of these vaccines have already been rolled out to immunize not only the highest risk individuals but also the general population in several countries. Once their safety and efficacy are established, the next limiting step would be their mass manufacturing by the pharmaceutical companies to fulfill the global demand. The challenge of manufacturing billions of doses of high-quality vaccines is under-appreciated at the moment. A massive vaccination drive would be needed to protect people of all ages. The timely and coordinated execution of the vaccination effort would require unprecedented coordination at the national and international levels for generating funds to purchase the required doses of vaccines, fair distribution of doses and managing the mechanics of delivering vaccines throughout the world.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9080836

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9080836